Find the buyers most likely to be in.
Set a target profile and get the strategic and financial buyers most likely to be relevant, ranked from verified European deal history. Deterministic scoring with published weights, defensible in a kickoff meeting. How the score works
Start from a company
Type any company, covered or not. We read its public footprint and pre-fill the profile.
Company name or website · covered or not, we pre-fill sector and country from its public footprint
Or build the profile yourself
Sector
The target's industry family
Sub-sector
Optional precision within the family
Country
Where the company operates from · 16 European markets
Target size (EV)
Optional · adds a check-size fit against each fund
Sector match
Strict keeps only buyers with in-sector deals · Broad admits neighbouring sectors
Geography match
Strict requires deals in the country itself · Broad counts the rest of Europe
Target: Ascend Advanced Therapies · Biotech · UK · scored as Biotech · United Kingdom, edit the profile above
How companies like this sold · 199 verified exits: 26% to sponsors, 65% to corporates and platforms, 7% via IPO, 2% other routes.
Route shift since 2020: sponsors 19% (was 41%), corporates and platforms 74% (was 47%), IPO 4% (was 11%).
Recent deals in this marketAlantra Private Equity Healthcare Continuation Fund closed Deudafix (2026) · Apax Partners closed Centor (2026) · Apax Partners (with NewAlpha) closed Centor (2026) · Apax Partners and Inova Capital closed Centor (2026) · Apax Partners and JMI Equity closed Centor (2026)
10 of the top 10 closed a deal in this space in the last 12 months.
Likely buyers · Biotech in United Kingdom.
Memo view · print-readyRanked by fit on sector, geography, recency, current exposure and timing. Strength labels and tiers are published thresholds, not editorial picks.
Financial buyers 9
| # | Buyer | Match | ||||
|---|---|---|---|---|---|---|
| Tier 1 · Very High · score 70+ | ||||||
| 1 | Inflexion | 85Very High | ||||
| 3 | Novo Holdings | 83Very High | ||||
| 4 | Inflexion (Partnership Capital III) | 83Very High | ||||
| 5 | NORD Holding | 83Very High | ||||
| 6 | Bridgepoint | 81Very High | ||||
| 7 | Bridgepoint Development Capital | 81Very High | ||||
| 8 | Bridgepoint (52.5% majority stake) | 81Very High | ||||
| 9 | Bridgepoint BE VII + General Atlantic | 81Very High | ||||
| 10 | Bridgepoint Capital | 81Very High | ||||
Strategic buyers 1
| # | Buyer | Match | ||||
|---|---|---|---|---|---|---|
| Tier 1 · Very High · score 70+ | ||||||
| 2 | Novartis | 84Very High | ||||
The full shortlist is open, precedents included. Pro adds the working tools.
Export the tiered buyer list to Excel, precedents and timing in the cells · Sourced press links on census add-on deals · Custom scoring weights